STRIANT SUMMARY
Striant® (testosterone buccal system) is designed to adhere to the gum or inner cheek. It provides a controlled and sustained release of testosterone through the buccal mucosa as the buccal system gradually hydrates. Insertion of Striant® twice a day, in the morning and in the evening, provides continuous systemic delivery of testosterone.
Striant® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:
Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range.
Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range.
|
NEWS HIGHLIGHTSMedia Articles Related to Striant (Testosterone)
Low Testosterone (Low T) Source: MedicineNet Iron Overload Specialty [2017.06.23] Title: Low Testosterone (Low T) Category: Symptoms and Signs Created: 5/22/2015 12:00:00 AM Last Editorial Review: 6/23/2017 12:00:00 AM
Published Studies Related to Striant (Testosterone)
Testosterone replacement therapy in older male subjective memory complainers:
double-blind randomized crossover placebo-controlled clinical trial of
physiological assessment and safety. [2015] Testosterone replacement therapy (TRT) has been investigated in older men as a
preventative treatment against Alzheimer's disease and dementia. However,
previous studies have been contradictory... Our study suggests TRT is safe and well-tolerated in
this Indonesian cohort, yet longitudinal studies with larger cohorts are needed
to assess TRT further, and to establish whether TRT reduces dementia risk.
Testosterone induces erythrocytosis via increased erythropoietin and suppressed
hepcidin: evidence for a new erythropoietin/hemoglobin set point. [2014] hematocrit remain unclear... CONCLUSIONS: Testosterone-induced increase in hemoglobin and hematocrit is
Effect of testosterone treatment on constitutional and sexual symptoms in men
with type 2 diabetes in a randomized, placebo-controlled clinical trial. [2014] constitutional and sexual symptoms in men with type 2 diabetes (T2D)... CONCLUSIONS: In this trial, T treatment did not substantially improve
The role of androgen receptor CAG repeat polymorphism and other factors which
affect the clinical response to testosterone replacement in metabolic syndrome
and type 2 diabetes: TIMES2 sub-study. [2013] TRT in the TIMES2 study... CONCLUSION: AR CAG affected the response of some variables to TRT in the TIMES2
Mechanical muscle function and lean body mass during supervised strength training
and testosterone therapy in aging men with low-normal testosterone levels. [2013] 24-week study... CONCLUSION: Strength training in aging men with low-normal testosterone levels
Clinical Trials Related to Striant (Testosterone)
Effect of Androgel on Type 2 Diabetic Males With Hypogonadism [Active, not recruiting]
This is to study the effect of replacing testosterone on different inflammatory cells in
type 2 diabetics with low testosterone levels.
Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women [Completed]
Female sexual dysfunction (FSD) is an established side effect of Selective serotonin
reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitors (SNRIs), causing
symptoms such as loss of libido, arousal difficulties, or delayed orgasm or anorgasmia.
Efficacy of testosterone therapy for the treatment of hypoactive sexual desire disorder
(HSDD) in women has been demonstrated in studies including naturally and surgically
menopausal women, either alone or in combination with estrogen, with or without progestin
therapy.
TRADE-Testosterone Replacement and Dutasteride Effectiveness [Completed]
The purpose of this research study is to determine whether the combination of the male
hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large
prostate glands can safely reduce the size of the prostate gland and symptoms of prostate
enlargement (called benign prostatic hyperplasia [BPH]) compared to T treatment alone in men
with low testosterone (called hypogonadism).
Pharmacokinetic Study of Testosterone Enanthate [Completed]
Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men [Recruiting]
Skeletal muscle loss is a common consequence of aging and in some individuals reaches a
level that compromises health and quality of life. Age-associated increases in cytokine and
inflammatory signaling may be important contributors to this process. In this project the
investigators will test the hypotheses that 1) testosterone will inhibit cytokine and
inflammatory signaling in skeletal muscles of older adults and 2) will augment the anabolic
response to increased skeletal muscle activity. The investigators will also assess the
practical question of whether testosterone injection and gel application elicit similar
responses. Resistance exercise will be used as a means of stimulating both inflammatory and
anabolic responses in skeletal muscle. In order to assess the effects of testosterone on
these responses, fourteen subjects will perform resistance exercise on two occasions
separated by 7 days. The first session will be performed prior to the initiation of
testosterone therapy and the second session will be performed after receiving testosterone
for 7 days.
|